

Form PTO-1449 (modified)

Atty. Docket No.
UTSC:684USSerial No.
10/010,763

List of Patents and Publications for Applicant's

Applicant

Isajah J. Fidler

Corazon D. Bucana

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

November 2, 2001

Group:

1642

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C34	Pollack et al. "Therapy of human carcinomas in athymic mice by inhibition of egf receptor-mediated signal transduction with cp-358774: dynamics of receptor inhibition and anti-tumor effects," <i>Proc Annu Meet Am Assoc Cancer Res</i> , Abstract 4249, 1997.
	C35	Pollack et al., "Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with cp-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice," <i>JPET</i> , 291739-748, 1999.
	C36	Prewett et al., "Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice," <i>Clinical Cancer Research</i> , 4:2957-2966, 1998.
	C37	Prewett et al., "The biologic effects of C225, a chimeric monoclonal antibody to the egfr, on human prostate carcinoma," <i>J of Immunotherapy</i> , 19:419-427, 1997.
	C38	Scardino and Wheeler, "Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy," <i>NCI Monogr.</i> 7:95-103, 1988.

25511056.1

EXAMINER:

DATE CONSIDERED:

5/31/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)